Survodutide Dosage Chart & Schedule
An investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors, studied for obesity and metabolic liver disease (MASH).
Survodutide is an investigational once-weekly GLP-1/glucagon dual receptor agonist given subcutaneously and titrated slowly upward. Phase 2 obesity trials escalated weekly doses up to roughly 4.8 mg; it has also been studied in metabolic liver disease (MASH) and is not approved.
Figures describe how Survodutide is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once weekly
- Weekly total
- ~0.6-1.2 mg
- Cycle
- Titrate up over weeks
Trials began at low weekly doses before escalating.
- Frequency
- Once weekly
- Weekly total
- ~2.4 mg
- Cycle
- Titrate up over weeks
An intermediate dose on the way to the trial target.
- Frequency
- Once weekly
- Weekly total
- up to ~4.8 mg
- Cycle
- Ongoing in trials
Approximate top weekly dose studied in phase 2 obesity trials.
Dual GLP-1/glucagon agonist
- Combines GLP-1 appetite and glucose effects with glucagon-receptor activation linked to energy expenditure and hepatic effects.
- Studied for both obesity and metabolic liver disease (MASH).
Investigational
- Not approved for any use; doses shown are approximate figures from clinical trials, not a recommendation.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the maintenance (trial target) protocol (Once weekly).
Dosing day Off
Survodutide reconstitution
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe (~40 units for 2 mg).
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- Reconstitute the lyophilized powder with bacteriostatic water (a 10 mg vial in about 2 mL gives 5,000 mcg/mL) and swirl gently.
- Give as a once-weekly subcutaneous injection on a U-100 syringe, rotating sites.
- Refrigerate the reconstituted vial and protect it from light.
Survodutide dosing FAQ
How often is survodutide dosed?
It is long-acting and was administered once weekly by subcutaneous injection in trials.
What is the highest weekly dose studied?
Phase 2 obesity trials escalated weekly subcutaneous doses up to roughly 4.8 mg.
Why is the dose titrated slowly?
Slow escalation is used across the GLP-1 class to reduce gastrointestinal effects such as nausea; the exact intermediate steps here are approximate.
Is survodutide approved?
No. It remains investigational for obesity and MASH, so all figures are research references rather than a human-use recommendation.
Sources
Categories: GLP-1 & Metabolic · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.